The global market for Exocrine Pancreatic Insufficiency was valued at USD 6.2 Billion in 2024 and is projected to reach USD 8.7 Billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Global Exocrine Pancreatic Insufficiency Market - Key Trends & Drivers Summarized
What Is Exocrine Pancreatic Insufficiency and How Is It Managed?
Exocrine pancreatic insufficiency (EPI) is a condition characterized by the pancreas' inability to produce or transport enough digestive enzymes, leading to malabsorption and digestive issues. It is commonly associated with conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic cancer. Managing EPI typically involves enzyme replacement therapy (ERT), where patients take pancreatic enzyme products (PEPs) to aid digestion and improve nutrient absorption. The growing awareness and diagnosis of EPI, combined with the availability of effective enzyme replacement therapies, are driving the demand for treatments and diagnostic solutions in the market.How Are Advancements in Diagnostic Techniques and Enzyme Formulations Impacting the Market?
Technological advancements in diagnostics and enzyme formulations have significantly impacted the exocrine pancreatic insufficiency market. Innovations in non-invasive diagnostic techniques, such as fecal elastase tests and advanced imaging technologies, enable early and accurate detection of EPI, leading to timely intervention. Moreover, pharmaceutical companies are developing advanced pancreatic enzyme formulations, including enteric-coated tablets and microencapsulated enzymes, which improve the efficacy of treatment and enhance patient compliance. These technological advancements are crucial in providing better therapeutic outcomes for patients, ensuring that treatments are both effective and convenient.Are Regulatory Approvals and Healthcare Accessibility Influencing Market Growth?
Regulatory approvals and the accessibility of healthcare significantly influence the EPI market. The approval of new enzyme replacement therapies by regulatory bodies like the FDA and EMA has expanded treatment options, ensuring that patients have access to safe and effective therapies. Additionally, the rise of healthcare infrastructure and accessibility, especially in emerging markets, supports the diagnosis and treatment of EPI. Increased awareness campaigns by healthcare providers and pharmaceutical companies also contribute to better patient education, encouraging individuals to seek diagnosis and treatment for symptoms of EPI. These trends underscore the importance of healthcare policies and regulatory frameworks in shaping the availability and adoption of EPI therapies globally.What Is Driving the Growth of the Exocrine Pancreatic Insufficiency Market?
The growth in the exocrine pancreatic insufficiency market is driven by several factors, including the rising prevalence of conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic cancer, which are primary causes of EPI. The development of advanced pancreatic enzyme replacement therapies, designed to enhance treatment efficacy and patient compliance, further propels the market. Additionally, technological advancements in diagnostic methods facilitate early and accurate detection, encouraging timely intervention and increasing the demand for enzyme therapies. Regulatory approvals and healthcare initiatives that improve access to EPI diagnosis and treatment also play a crucial role in market growth, ensuring that patients worldwide have access to effective management solutions for exocrine pancreatic insufficiency.Report Scope
The report analyzes the Exocrine Pancreatic Insufficiency market, presented in terms of market value (USD Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Type (Therapeutics, Diagnostics).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Exocrine Pancreatic Insufficiency Therapeutics segment, which is expected to reach $4.8 Billion by 2030 with a CAGR of a 5.5%. The Exocrine Pancreatic Insufficiency Diagnostics segment is also set to grow at 6.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $1.7 Billion in 2024, and China, forecasted to grow at an impressive 5.3% CAGR to reach $1.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in USD from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie, Inc., Allergan PLC, Anthera Pharmaceuticals, Inc., AzurRx BioPharma, Inc., Cilian AG and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Exocrine Pancreatic Insufficiency Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Exocrine Pancreatic Insufficiency Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Exocrine Pancreatic Insufficiency Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 46 major companies featured in this Exocrine Pancreatic Insufficiency market report include:
- AbbVie, Inc.
- Allergan PLC
- Anthera Pharmaceuticals, Inc.
- AzurRx BioPharma, Inc.
- Cilian AG
- Digestive Care, Inc.
- Janssen Pharmaceuticals, Inc.
- Nordmark Arzneimittel GmbH & Co. KG
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Allergan PLC
- Anthera Pharmaceuticals, Inc.
- AzurRx BioPharma, Inc.
- Cilian AG
- Digestive Care, Inc.
- Janssen Pharmaceuticals, Inc.
- Nordmark Arzneimittel GmbH & Co. KG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 6.2 Billion |
| Forecasted Market Value ( USD | $ 8.7 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
